UPEXI, INC. Faces Delisting Concerns
Ticker: UPXI · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1775194
| Field | Detail |
|---|---|
| Company | Upexi, Inc. (UPXI) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
UPEXI might get kicked off the exchange, big trouble.
AI Summary
UPEXI, INC. filed an 8-K on October 2, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The company, formerly known as GROVE, INC., is incorporated in Nevada and operates in the medicinal chemicals & botanical products sector.
Why It Matters
This filing indicates potential issues with UPEXI, INC.'s compliance with stock exchange listing requirements, which could lead to its shares being delisted.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading viability.
Key Players & Entities
- UPEXI, INC. (company) — Filer of the 8-K report.
- GROVE, INC. (company) — Former name of UPEXI, INC.
- 20241002 (date) — Date of the filing and earliest event reported.
- 0001775194 (company) — Central Index Key for UPEXI, INC.
FAQ
What specific listing rule or standard has UPEXI, INC. failed to satisfy?
The filing does not specify the exact rule or standard that UPEXI, INC. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the effective date of the delisting or transfer of listing?
The filing indicates the 'DATE AS OF CHANGE' is 20241002, suggesting this is the date the event is being reported or becoming effective.
What is the business address of UPEXI, INC.?
The business address is 3030 ROCKY POINT DRIVE, SUITE 420, TAMPA, FL 33607.
What was UPEXI, INC. formerly known as?
UPEXI, INC. was formerly known as GROVE, INC., with a name change date of 20190429.
What industry does UPEXI, INC. operate in?
UPEXI, INC. operates in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector, with SIC code 2833.
Filing Stats: 869 words · 3 min read · ~3 pages · Grade level 13.8 · Accepted 2024-10-02 16:31:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 UPXI NASDAQ Indicate by check mar
- $1.00 — n Stock ") had closed below the minimum $1.00 per share requirement for continued lis
Filing Documents
- upxi_8k.htm (8-K) — 26KB
- 0001477932-24-006162.txt ( ) — 151KB
- upxi-20241001.xsd (EX-101.SCH) — 6KB
- upxi-20241001_lab.xml (EX-101.LAB) — 15KB
- upxi-20241001_cal.xml (EX-101.CAL) — 1KB
- upxi-20241001_pre.xml (EX-101.PRE) — 9KB
- upxi-20241001_def.xml (EX-101.DEF) — 2KB
- upxi_8k_htm.xml (XML) — 4KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As disclosed in a Current Report on Form 8-K on April 2, 2024, on April 1, 2024, Upexi, Inc. (the " Company ") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company's common stock (the " Common Stock ") had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the " Minimum Bid Price Requirement "). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance. The Common Stock did not regain compliance with the Minimum Bid Price Requirement within such period. The Company timely requested, and was granted by Nasdaq on October 1, 2024, an additional 180 calendar days to regain compliance with the Minimum Bid Price Requirement. As disclosed in a Current Report on Form 8-K on September 26, 2024, the Company intends to effect a reverse stock split at 12:01 am ET, October 3, 2024, with the intent of regaining compliance with the Minimum Bid Price Requirement.
Forward-Looking Statements
Forward-Looking Statements Certain statements and information included in this current report constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this current report, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including final rules implemented under the No Surprises Act and related regulatory guidance, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Company's Annual Report on form 10-K for the year ended June 30, 2023 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2023, and December 31, 2023, under the heading "Risk Factors" in Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to diffe
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UPEXI, INC. Dated: October 2, 2024 /s/ Andrew J. Norstrud Name: Andrew J. Norstrud Title: Chief Financial Officer 3